InMed Pharmaceuticals Net Worth
InMed Pharmaceuticals Net Worth Breakdown | INM |
InMed Pharmaceuticals Net Worth Analysis
InMed Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including InMed Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of InMed Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform InMed Pharmaceuticals' net worth analysis. One common approach is to calculate InMed Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares InMed Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing InMed Pharmaceuticals' net worth. This approach calculates the present value of InMed Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of InMed Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate InMed Pharmaceuticals' net worth. This involves comparing InMed Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into InMed Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if InMed Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding InMed Pharmaceuticals' net worth research are outlined below:
| InMed Pharmaceuticals had very high historical volatility over the last 90 days | |
| InMed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.6 M. Reported Net Loss for the year was (7.68 M) with profit before taxes, overhead, and interest of 1.4 M. | |
| InMed Pharmaceuticals has about 9.35 M in cash with (6.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InMed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System |
InMed Pharmaceuticals Quarterly Good Will |
|
InMed Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in InMed Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to InMed Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 16th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know InMed Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as InMed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading InMed Pharmaceuticals backward and forwards among themselves. InMed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase InMed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 6.0 | The Toronto-dominion Bank | 2024-06-30 | 2.0 | Bfsg, Llc | 2024-06-30 | 0.0 | Td Waterhouse Canada Inc | 2024-09-30 | 0.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Advisornet Financial, Inc | 2024-06-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Advisorshares Investments, Llc | 2024-09-30 | 733.3 K | Sabby Management Llc | 2024-06-30 | 307.2 K |
Follow InMed Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a total capitalization of 3.78 M.Market Cap |
|
Project InMed Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (4.61) | |
| Return On Capital Employed | 5.93 | 6.23 | |
| Return On Assets | (0.65) | (2.78) | |
| Return On Equity | (0.83) | 6.45 |
When accessing InMed Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures InMed Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of InMed Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate InMed Pharmaceuticals' management efficiency
InMed Pharmaceuticals has Return on Asset of (0.3922) % which means that on every $100 spent on assets, it lost $0.3922. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7209) %, meaning that it generated no profit with money invested by stockholders. InMed Pharmaceuticals' management efficiency ratios could be used to measure how well InMed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, InMed Pharmaceuticals' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 6.45, while Return On Tangible Assets are likely to drop (4.61). At this time, InMed Pharmaceuticals' Tangible Asset Value is very stable compared to the past year. As of the 15th of December 2024, Intangibles To Total Assets is likely to grow to 0.40, while Net Tangible Assets are likely to drop about 9.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.21 | (17.32) | |
| Net Current Asset Value | -39.7 K | -41.7 K | |
| Tangible Asset Value | 1.5 M | 2 M | |
| Tangible Book Value Per Share | 0.98 | (33.20) | |
| Enterprise Value Over EBITDA | (4.61) | (2.02) | |
| Price Book Value Ratio | 4.14 | (7.61) | |
| Enterprise Value Multiple | (4.61) | (2.02) | |
| Price Fair Value | 4.14 | (7.61) | |
| Enterprise Value | 32.5 M | 1.9 M |
Leadership effectiveness at InMed Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 14.648 | Revenue 4.6 M | Quarterly Revenue Growth (0.45) | Revenue Per Share 0.603 | Return On Equity (0.72) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific InMed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on InMed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases InMed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
InMed Pharmaceuticals Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 28th of October 2024 Other Reports | ViewVerify | |
| 17th of October 2024 Other Reports | ViewVerify |
InMed Pharmaceuticals Earnings per Share Projection vs Actual
InMed Pharmaceuticals Corporate Management
| Sazzad MSc | CoFounder | Profile | |
| Ado Muhammad | Consultant Affairs | Profile | |
| Colin Clancy | Director Relations | Profile | |
| Eric Hsu | Senior Development | Profile | |
| Jerry Griffin | Vice Marketing | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.